Sanofi (SNY)

NASDAQ: SNY · IEX Real-Time Price · USD
52.90
0.34 (0.65%)
May 17, 2022 4:00 PM EDT - Market closed
Market Cap132.11B
Revenue (ttm)44.52B
Net Income (ttm)7.07B
Shares Out2.50B
EPS (ttm)2.75
PE Ratio19.23
Forward PE12.85
Dividend$1.30 (2.45%)
Ex-Dividend DateMay 4, 2022
Volume1,749,845
Open52.80
Previous Close52.56
Day's Range52.60 - 53.14
52-Week Range46.93 - 58.10
Beta0.44
AnalystsBuy
Price Target59.66 (+12.8%)
Earnings DateApr 28, 2022

About SNY

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established p...

IndustryPharmaceuticals
CEOPaul Hudson
Employees95,442
Stock ExchangeNASDAQ
Ticker SymbolSNY
Full Company Profile

Financial Performance

In 2021, Sanofi's revenue was 39.18 billion, an increase of 4.83% compared to the previous year's 37.37 billion. Earnings were 6.22 billion, a decrease of -49.38%.

Financial numbers in millions EURFinancial Statements

Analyst Forecast

According to 33 analysts, the average rating for SNY stock is "Buy." The 12-month stock price forecast is 59.66, which is an increase of 12.78% from the latest price.

Price Target
$59.66
(12.78% upside)
Analyst Consensus: Buy
Stock Forecasts

News

European Dividend Aristocrats: 40 Top International Dividend Stocks

U.S. equity markets aren't the only place where you can find income-producing royalty. Indeed, a quick look across the pond yields dozens, in the form of the European Dividend Aristocrats.

Other symbols:UL
1 day ago - Kiplinger

Sanofi ordered to compensate French family for epilepsy drug side effects

A French court has ordered Sanofi to pay more than 400,000 euros ($416,440) in damages to a family whose child suffered from a form of autism caused by its epilepsy drug Valproate, saying the drugmaker ...

3 days ago - Reuters

3 Top Biotech Stocks to Buy Right Now

These three pharma stocks each pay market-beating dividends to shareholders.

Other symbols:AZNPFE
1 week ago - The Motley Fool

EuroAPI gains on market debut after spin-off from Sanofi

Shares in EuroAPI, the drug ingredients business spun off from Sanofi, rose on their Paris stock market debut on Friday, defying a wider market decline.

1 week ago - Reuters

Press Release: Foundation S: Sanofi's new philanthropic spearhead

Sanofi today launches Foundation S – The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partnerships and collective action, Foun...

1 week ago - GlobeNewsWire

Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise

Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines.

2 weeks ago - Zacks Investment Research

Sanofi posts higher earnings and sales, sees further growth ahead

Sanofi SA on Thursday posted higher earnings and sales for the first quarter, driven by best-selling drug Dupixent and consumer healthcare, and said that it expects further growth in business earnings p...

2 weeks ago - Market Watch

Sanofi operating income up 16% on bestseller drug Dupixent

French healthcare group Sanofi's first quarter adjusted earnings gained 16.2% on continued sales growth of its bestselling drug Dupixent.

2 weeks ago - Reuters

Press Release: Sanofi continues to deliver strong business EPS growth driven by higher sales and improved margins in Q1

Sanofi continues to deliver strong business EPS ( 1) growth driven by higher sales and improved margins in Q1

2 weeks ago - GlobeNewsWire

Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More

Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.

Other symbols:EBSGILDLLYMRK
2 weeks ago - Zacks Investment Research

Should You Buy Sanofi (SNY) Ahead of Earnings?

Sanofi (SNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 weeks ago - Zacks Investment Research

Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence

Sanofi announces today that it is partnering with McLaren Racing to accelerate manufacturing efficiency and performance in support of the company's ambition to attain world-class standards of manufactur...

3 weeks ago - GlobeNewsWire

Sempre Health Improved Medication Adherence by 25% for Diabetes Patients Prescribed Sanofi Medications

Collaboration Supports Companies' Joint Focus on Medication Adherence and Affordability SAN FRANCISCO , April 13, 2022 /PRNewswire/ -- Today, Sempre Health announced compelling outcomes achieved during ...

1 month ago - PRNewsWire

Sanofi - AGM 03.05.2022 - Availability of Preparatory Documents

The Company's shareholders are invited to attend the Combined General Meeting to be held on Tuesday May 3, 2022 at 2:30 p.m. (CET) at Paris Expo Porte de Versailles – 1, Place de la Porte de Versailles,...

1 month ago - GlobeNewsWire

Could This Drug Candidate Be a Blockbuster for Sanofi?

The pharma giant recently shared encouraging results from a late-stage clinical trial for its hemophilia drug candidate.

1 month ago - The Motley Fool

Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids

Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.

Other symbols:REGN
1 month ago - Zacks Investment Research

Sanofi (SNY) Stock Outperforms Industry YTD: What Lies Ahead?

Here we discuss some factors that have been driving Sanofi's (SNY) stock and its outlook for the future.

1 month ago - Zacks Investment Research

Regeneron (REGN), Sanofi Get Priority Review for Dupixent sBLA

The FDA accepts and grants priority review to Regeneron (REGN) and Sanofi's sBLA for Dupixent to treat eosinophilic esophagitis in patients aged 12 years and older. A decision is due on Aug 3, 2022.

Other symbols:REGN
1 month ago - Zacks Investment Research

Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board

Sanofi's DE&I strategy was revamped in June 2021 with set objectives toward 2025, built around three key pillars: building representative leadership, creating a work environment where employees can brin...

1 month ago - GlobeNewsWire

Sanofi to list drug ingredients business on May 6

Sanofi expects to list its drug ingredients business EUROAPI on May 6, having received approval from French stock market regulator, the pharmaceutical giant said on Friday.

1 month ago - Reuters

Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022

Sanofi announced today that the French Autorité des marchés financiers (AMF) has approved the listing prospectus prepared by EUROAPI

1 month ago - GlobeNewsWire

Regeneron, IGM Biosciences Shares Up Big on Sanofi Deals

A week filled with promising announcements failed to jump-start Sanofi SA's ( SNY , Financial) shares, but it did for the two companies it's working with.

Other symbols:IGMSREGN
1 month ago - GuruFocus

France's Sanofi offers 1.5 billion euro bond linked to access to medicine

French healthcare group Sanofi said it had priced a first sustainability-linked bond issue that will be indexed on access to medicines, and worth 1.5 billion euros ($1.7 billion).

1 month ago - Reuters

Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines

Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines

1 month ago - GlobeNewsWire

IGM (IGMS) Skyrockets on Collaboration Deal With Sanofi

IGM Biosciences (IGMS) inks a deal with Sanofi (SNY) to discover and develop new therapies based on its proprietary technology, which is set to target oncology, immunology and inflammation targets.

1 month ago - Zacks Investment Research